Enanta Pharmaceuticals, Inc. (ENTA) Forms $87.50 Double Top; Last Week Manning & Napier, Inc. (MN) Analysts

Manning & Napier, Inc. (NYSE:MN) Logo

Among 7 analysts covering Manning & Napier Advisors (NYSE:MN), 0 have Buy rating, 3 Sell and 4 Hold. Therefore 0 are positive. Manning & Napier Advisors had 20 analyst reports since August 3, 2015 according to SRatingsIntel. The company was maintained on Thursday, September 3 by Wood. Keefe Bruyette & Woods maintained it with “Hold” rating and $400 target in Tuesday, August 1 report. Keefe Bruyette & Woods maintained it with “Hold” rating and $4.0 target in Friday, October 6 report. Keefe Bruyette & Woods maintained it with “Hold” rating and $4.0 target in Friday, November 10 report. The stock of Manning & Napier, Inc. (NYSE:MN) earned “Sell” rating by Wood on Tuesday, April 11. The stock of Manning & Napier, Inc. (NYSE:MN) has “Mkt Perform” rating given on Wednesday, June 14 by Keefe Bruyette & Woods. Keefe Bruyette & Woods maintained the stock with “Hold” rating in Friday, July 21 report. JP Morgan maintained the stock with “Underweight” rating in Tuesday, September 8 report. Keefe Bruyette & Woods downgraded Manning & Napier, Inc. (NYSE:MN) on Thursday, October 27 to “Underperform” rating. Keefe Bruyette & Woods maintained the stock with “Hold” rating in Monday, September 4 report. See Manning & Napier, Inc. (NYSE:MN) latest ratings:

10/11/2017 Broker: Keefe Bruyette & Woods Rating: Hold New Target: $4.0 Maintain
03/11/2017 Broker: Needham Rating: Hold Maintain

Enanta Pharmaceuticals, Inc. (ENTA) formed double top with $90.13 target or 3.00% above today’s $87.50 share price. Enanta Pharmaceuticals, Inc. (ENTA) has $1.68 billion valuation. The stock decreased 0.50% or $0.44 during the last trading session, reaching $87.5. About 86,979 shares traded. Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) has risen 160.80% since April 25, 2017 and is uptrending. It has outperformed by 149.25% the S&P500.

Manning & Napier, Inc. is publicly owned investment manager. The company has market cap of $249.46 million. It provides its services to net worth individuals and institutions, including 401 plans, pension plans, taft-hartley plans, endowments and foundations. It has a 12.7 P/E ratio. The firm manages separate client-focused equity and fixed income portfolios.

It closed at $3.15 lastly. It is up 35.14% since April 25, 2017 and is downtrending. It has underperformed by 46.69% the S&P500.

Investors sentiment increased to 1.09 in Q4 2017. Its up 0.39, from 0.7 in 2017Q3. It increased, as 5 investors sold Manning & Napier, Inc. shares while 17 reduced holdings. 11 funds opened positions while 13 raised stakes. 8.02 million shares or 5.12% more from 7.63 million shares in 2017Q3 were reported. Wealthtrust holds 0% in Manning & Napier, Inc. (NYSE:MN) or 625 shares. Vanguard Grp Inc stated it has 382,732 shares. Citadel Ltd Co accumulated 0% or 10,155 shares. Geode Cap Limited Liability Company accumulated 117,645 shares. Mufg Americas Corporation invested in 0% or 215 shares. Brandywine Global Mngmt Limited Liability Corp holds 63,300 shares. Renaissance Tech Ltd Liability Corp reported 1.21M shares. Dimensional Fund L P holds 0% or 416,981 shares. Ariel Invs Ltd Liability has invested 0.04% of its portfolio in Manning & Napier, Inc. (NYSE:MN). Bnp Paribas Arbitrage Sa accumulated 0% or 22 shares. Thomas J Herzfeld Advisors Inc has 5,900 shares. Barclays Plc holds 0% or 16,290 shares in its portfolio. Susquehanna Group Inc Ltd Liability Partnership has 26,145 shares. Qs Limited Liability invested 0% in Manning & Napier, Inc. (NYSE:MN). Sg Americas Secs Ltd Limited Liability Company holds 0% or 14,653 shares in its portfolio.

Analysts await Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) to report earnings on May, 14. They expect $0.09 EPS, up 132.14% or $0.37 from last year’s $-0.28 per share. ENTA’s profit will be $1.72 million for 243.06 P/E if the $0.09 EPS becomes a reality. After $0.78 actual EPS reported by Enanta Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -88.46% negative EPS growth.

Among 6 analysts covering Enanta Pharmaceuticals Inc (NASDAQ:ENTA), 1 have Buy rating, 1 Sell and 4 Hold. Therefore 17% are positive. Enanta Pharmaceuticals Inc has $82.0 highest and $16 lowest target. $47.60’s average target is -45.60% below currents $87.5 stock price. Enanta Pharmaceuticals Inc had 24 analyst reports since August 7, 2015 according to SRatingsIntel. As per Monday, November 20, the company rating was maintained by RBC Capital Markets. Robert W. Baird maintained Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) on Thursday, February 8 with “Hold” rating. J.P. Morgan downgraded the stock to “Hold” rating in Thursday, February 8 report. As per Friday, August 7, the company rating was downgraded by Zacks. The company was downgraded on Friday, October 23 by Barclays Capital. Robert W. Baird maintained Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) rating on Tuesday, August 8. Robert W. Baird has “Neutral” rating and $36 target. The firm has “Buy” rating by TheStreet given on Saturday, August 8. RBC Capital Markets maintained Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) rating on Wednesday, April 4. RBC Capital Markets has “Hold” rating and $8000 target. Robert W. Baird maintained the stock with “Hold” rating in Friday, September 15 report. The rating was maintained by Robert W. Baird on Friday, October 20 with “Hold”.

Since March 19, 2018, it had 0 buys, and 2 selling transactions for $1.14 million activity. The insider MELLETT PAUL J sold 9,000 shares worth $778,331. Shares for $361,560 were sold by Adda Nathalie on Monday, April 16.

Investors sentiment decreased to 1.58 in 2017 Q4. Its down 0.02, from 1.6 in 2017Q3. It turned negative, as 12 investors sold Enanta Pharmaceuticals, Inc. shares while 36 reduced holdings. 29 funds opened positions while 47 raised stakes. 13.64 million shares or 12.66% more from 12.10 million shares in 2017Q3 were reported. Rhumbline Advisers invested in 36,475 shares. 7,558 are owned by Voya Investment Mngmt Limited Liability. Deutsche National Bank Ag accumulated 37,499 shares or 0% of the stock. Aqr Cap Lc accumulated 155,182 shares or 0.01% of the stock. Farallon Capital Llc invested in 0.44% or 925,000 shares. Hbk Investments L P owns 3,761 shares or 0% of their US portfolio. Granahan Investment Mngmt Ma has 89,811 shares. Clarivest Asset Management Ltd Liability holds 15,200 shares or 0.02% of its portfolio. Mcclain Value Mngmt Ltd holds 2.93% or 37,810 shares in its portfolio. Adams Diversified Equity Fund Inc, a Maryland-based fund reported 10,800 shares. Bank Of New York Mellon reported 174,114 shares. Employees Retirement System Of Ohio holds 0.01% or 18,613 shares in its portfolio. Vanguard Gp owns 821,687 shares. 99,548 are owned by Ajo Ltd Partnership. Ameriprise Financial Inc invested in 153,073 shares.

Manning & Napier, Inc. (NYSE:MN) Institutional Positions Chart